Global /Japan /Healthcare /Drug Manufacturers - General /190A

Chordia Therapeutics Inc.

190A

• TSE: 190A • Delayed

150JPY -3.2%

0.9373 USD

As of 5 June 2026, Chordia Therapeutics Inc. has a market cap of $69.11M USD, ranking #28218 globally and #2548 in Japan. It ranks #2551 in the Healthcare sector, and #913 in the Drug Manufacturers - General industry.

Global Rank

28218

Country Rank

2548

Sector Rank

2551

Industry Rank

913

Key Stats

Market Cap

$69.11MUSD

11.06B JPY

Enterprise Value

$53.82MUSD

8.61B JPY

EBITDA (TTM)

-$9.08MUSD

-1.45B JPY

Net Income (TTM)

-$9.02MUSD

-1.44B JPY

PB Ratio

4.8

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Hiroshi Miyake open_in_new

Employees

Founded

2017

Website

chordiatherapeutics.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.2%	-2%	14%	17%	36%	39%	-38%	-59%	-59%

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	190A ＣｈｏｒｄｉａＴｈｅｒａｐｅｕｔｉｃｓ株式会社 ISIN: JP3283730004 Shares Out.: Shares Outstanding: 76.392M¹ Shares Float: 22.12M² TV: TradingView: TSE: 190A SA: Stock Analysis: TYO: 190A YF: Yahoo Finance: 190A.T GF: Google Finance: TYO: 190A BA: Barron's: 190A MS: Morningstar: XTKS: 190A	150 JPY	TV: TradingView: TSE: 190A SA: Stock Analysis: TYO: 190A YF: Yahoo Finance: 190A.T GF: Google Finance: TYO: 190A BA: Barron's: 190A MS: Morningstar: XTKS: 190A

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Chordia Therapeutics Inc.

Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.

Similar Companies

Industry: Drug Manufacturers - General (Japan)

Name	Market Cap (USD) diff.	PE	Country
Chugai Pharmaceutical Co., Ltd. TSE: 4519	$81.66B 13.07T JPY 118K%	28.9	Japan
Takeda Pharmaceutical Company Ltd. TSE: 4502	$52.21B 8.36T JPY 75K%	75.1	Japan
Otsuka Holdings Co., Ltd. TSE: 4578	$36.84B 5.9T JPY 53K%	15.7	Japan
Daiichi Sankyo Company, Ltd. TSE: 4568	$30.37B 4.86T JPY 44K%	16.2	Japan
Astellas Pharma Inc. TSE: 4503	$25.82B 4.13T JPY 37K%	14.2	Japan
Shionogi & Co., Ltd. TSE: 4507	$16.91B 2.71T JPY 24K%	13.9	Japan

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 1M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 792K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 522K%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 470K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 419K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 401K%	20.5	Switzerland

chevron_leftBack